Corbus Pharmaceuticals Holdings, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-963-0100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.82 million
Profitability
Miscellaneous
Employees77
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions
What is Corbus Pharmaceuticals' stock symbol?
Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."
How were Corbus Pharmaceuticals' earnings last quarter?
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) announced its earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.02 by $0.45. The biopharmaceutical company had revenue of $1.89 million for the quarter, compared to analyst estimates of $20.97 million. Corbus Pharmaceuticals had a negative return on equity of 166.99% and a negative net margin of 1,219.36%. View Corbus Pharmaceuticals' Earnings History.
When is Corbus Pharmaceuticals' next earnings date?
What price target have analysts set for CRBP?
7 Wall Street analysts have issued 1-year price objectives for Corbus Pharmaceuticals' stock. Their predictions range from $18.00 to $38.00. On average, they anticipate Corbus Pharmaceuticals' stock price to reach $25.8571 in the next year. This suggests a possible upside of 262.1% from the stock's current price. View Analyst Price Targets for Corbus Pharmaceuticals.
What is the consensus analysts' recommendation for Corbus Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corbus Pharmaceuticals.
What are Wall Street analysts saying about Corbus Pharmaceuticals stock?
Here are some recent quotes from research analysts about Corbus Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. " (5/20/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our price target of $24/share is based on an equally weighted composite of: (a) $23.83/share, as a 35x multiple of taxed and diluted $5.60 discounted back to FY19 at 18% (in line with the expected P/E multiple and discount rate of an early development stage biotechnology company); and (b) an NPV of $24/share (discounted cash flow analysis using a 15.5% discount rate and 2% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (5/10/2019)
Has Corbus Pharmaceuticals been receiving favorable news coverage?
News coverage about CRBP stock has been trending somewhat negative on Thursday, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Corbus Pharmaceuticals earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Corbus Pharmaceuticals.
Who are some of Corbus Pharmaceuticals' key competitors?
Some companies that are related to Corbus Pharmaceuticals include AnaptysBio (ANAB), Pacira Biosciences (PCRX), Enanta Pharmaceuticals (ENTA), Ironwood Pharmaceuticals (IRWD), Biohaven Pharmaceutical (BHVN), Zogenix (ZGNX), Supernus Pharmaceuticals (SUPN), Prestige Consumer Healthcare (PBH), Madrigal Pharmaceuticals (MDGL), Nabriva Therapeutics (NBRV), Gossamer Bio (GOSS), Cambrex (CBM), Innoviva (INVA), Apellis Pharmaceuticals (APLS) and Heron Therapeutics (HRTX).
What other stocks do shareholders of Corbus Pharmaceuticals own?
Who are Corbus Pharmaceuticals' key executives?
Corbus Pharmaceuticals' management team includes the folowing people:
- Dr. Yuval Cohen, CEO & Director (Age 44)
- Mr. Sean F. Moran CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 61)
- Dr. Mark A. Tepper, Co-Founder & Consultant (Age 62)
- Dr. Barbara White, Chief Medical Officer (Age 69)
- Ted Jenkins, Sr. Director of Investor Relations & Communications
Who are Corbus Pharmaceuticals' major shareholders?
Corbus Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (1.87%), General American Investors Co. Inc. (0.86%), Raymond James Financial Services Advisors Inc. (0.47%), Creative Planning (0.37%), Alps Advisors Inc. (0.23%) and Stephens Inc. AR (0.12%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, Craig Stuart Millian, David P Hochman, John Kenneth Jenkins, Sean F Moran and Yuval Cohen. View Institutional Ownership Trends for Corbus Pharmaceuticals.
Which institutional investors are selling Corbus Pharmaceuticals stock?
Which institutional investors are buying Corbus Pharmaceuticals stock?
CRBP stock was acquired by a variety of institutional investors in the last quarter, including General American Investors Co. Inc., Stephens Inc. AR, Creative Planning, P.A.W. Capital Corp, Bank of Montreal Can, Alps Advisors Inc., IPG Investment Advisors LLC and Cetera Advisor Networks LLC. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Barbara White, Craig Stuart Millian, David P Hochman, John Kenneth Jenkins, Sean F Moran and Yuval Cohen. View Insider Buying and Selling for Corbus Pharmaceuticals.
How do I buy shares of Corbus Pharmaceuticals?
Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corbus Pharmaceuticals' stock price today?
One share of CRBP stock can currently be purchased for approximately $7.14.
How big of a company is Corbus Pharmaceuticals?
Corbus Pharmaceuticals has a market capitalization of $460.24 million and generates $4.82 million in revenue each year. The biopharmaceutical company earns $-55,670,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Corbus Pharmaceuticals employs 77 workers across the globe.View Additional Information About Corbus Pharmaceuticals.
What is Corbus Pharmaceuticals' official website?
How can I contact Corbus Pharmaceuticals?
Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]
MarketBeat Community Rating for Corbus Pharmaceuticals (NASDAQ CRBP)
MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
